

CLAIMS

1. A lactic composition comprising a mixture of bacterial strain, *Lactobacillus acidophilus* and *Lactobacillus casei*, and a whole broth of said mixture, characterized in that the lactic composition is for the prevention or the treatment of angiogenesis dependant disorders.
2. A lactic composition according to claim 1, characterized in that the at least one *Lactobacillus acidophilus* strain is strain I-1492 deposited at the CNCM.
3. A lactic composition according to claim 2, characterized in that it comprises at least 500 millions per gram of a population of living and active micro-organisms of the *Lactobacillus acidophilus* strains after 90 days under refrigeration, where at least 380 millions per gram are micro-organisms of the *Lactobacillus acidophilus* CNCM I-1492 strain.
4. A lactic composition according to claim 3, characterized in that it further comprises fermented milk proteins or fermented soy proteins.
5. - A supernatant obtained from the lactic composition as defined in any one of claims 1 to 4, characterized in that said supernatant exhibits antiangiogenic properties.
6. The supernatant according to claim 5, characterized in that said supernatant is concentrated.
7. The supernatant according to claims 5 or 6, characterized in that said supernatant is 10X concentrated.
8. The supernatant according to any one of claims 5 to 7, characterized in that it comprises molecules of a size larger than 5000 kDa.

9. Use of the supernatant as defined in any one of claims 5 to 8, as an antiangiogenic agent.
10. Use of the supernatant as defined in any one of claims 5 to 8, in the prevention or the treatment of an angiogenesis dependant disorder in a mammal.
11. Use according to claim 10, wherein said mammal is a human being.
12. Use according to claim 10, wherein said disorder is selected from the group consisting of retinopathy, infantile haemangioma, rheumatoid arthritis, psoriasis, duodenal ulcers, post-angioplasty restenosis and tumour growth.
13. Use of a supernatant according to claim 12, wherein said disorder is tumour growth.
14. Use of the lactic composition as defined in any one of claims 1 to 4, as an antiangiogenic agent.
15. Use of the lactic composition as defined in any one of claims 1 to 4, in the prevention or the treatment of an angiogenesis dependant disorder in an mammal.
16. Use according to claim 15, wherein said mammal is a human being.
17. Use according to claim 15, wherein said disorder is selected from the group consisting of retinopathy, infantile haemangioma, rheumatoid arthritis, psoriasis, duodenal ulcers, post-angioplasty restenosis and tumour growth.
18. Use according to claim 17, wherein said disorder is tumour growth.
19. Method for prevention or treatment of an angiogenesis dependant disorder, the method comprising the step of administering to a mammal an effective

amount of the lactic composition as defined in anyone of claims 1 to 4 or of the supernatant as defined in any one of claims 5 to 8.

20. Method according to claim 19, wherein said mammal is a human being.

21. Method according to claim 19, wherein said disorder is selected from the group consisting of retinopathy, infantile haemangioma, rheumatoid arthritis, psoriasis, duodenal ulcers, post-angioplasty restenosis and tumour growth.

22. Method according to claim 21, wherein said disorder is tumour growth.

23. Method according to any one of claims 19 to 22, wherein said administration
——— is oral administration.